FDA Grants Priority Review For Roche’s NDA For Giredestrant In Breast Cancer

Roche Holding AG (RHHBY), a healthcare company, reported that its New Drug Application seeking approval for Giredestrant as an adjuvant treatment for patients with stage I-III ER+/HER- breast cancer has been accepted for priority review by the FDA.